ISRCTN85022211进行中（未招募）2 期
Intravitreal panitumumab combined with intravitreal ranibizumab for exudative age-related macular degeneration
fa Eye Research Institute0 个研究点目标入组 200 人开始时间: 2023年12月20日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Best corrected visual acuity of <0.30 (decimal)
- •2. Foveal retinal thickness (measured from Bruch´s membrane to the inner limiting membrane, i.e. including the retinal pigment epithelium layer) of >300µm
- •3. Normal intraocular pressure
- •4. Transparent optical media
- •5. Absence of any other eye disease (except for cataract or pseudophakia)
- •6. No previous retinal or vitreoretinal surgery (except for peripheral retinal argon laser coagulation)
排除标准
- •1. Inability to attend the follow-up examinations
- •2. Inability to understand the purpose and structure of the study.
研究者
相似试验
进行中（未招募）
1 期
Panitumumab to prevent the progression of eyeball elongation in adults with nearsightedness and macular degeneratioAdult highly myopic patients with myopic macular degenerationEye DiseasesISRCTN96896687fa Eye Research Institute20
招募中
1 期
Intravitreal Panitumumab for Prevention of Myopic Axial Elongation in Highly Myopic Adult Eyes with Myopic Macular DegeneratioMyopic ophthalmopathyDRKS00027302fa Eye Research Institute40
已完成
不适用
Combination therapy with intravitreal tissue plasminogen activator and ranibizumab for subfoveal type 2 choroidal neovascularizatioSubfoveal type 2 choroidal neovascularizationJPRN-UMIN000016870agoya City University Graduate School of Medicine20
招募中
不适用
Combination Treatment of Intravitreal Ranibizumab, focal/Grid Laser and panretinal photocoagulation in patients with diabetic macular edemadiabetic macula edemaJPRN-UMIN000012549Shinshu university school of medicine Department of Ophthalmology40
已完成
不适用
Intravitreal bevacizumab injection for intraocular neovascularization in childreRetinopathy of prematurityJPRN-UMIN000014316Kansai Medical University15